Cynata Therapeutics Ltd. has announced the completion of patient enrolment in its Phase 2 clinical trial of CYP-001 for the treatment of acute graft versus host disease (aGvHD). The trial has enrolled 65 participants across the US, Europe, and Australia, who were randomised to receive either steroids plus CYP-001 or steroids plus placebo. The primary evaluation period will conclude in March 2026, with results expected in June 2026. The results have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cynata Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN47111) on December 15, 2025, and is solely responsible for the information contained therein.